Here are the top 5 biosimilar articles for the week of June 7, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of June 7, 2021.
Number 5: Bio-Thera Solutions initiated a phase 3 clinical study for its golimumab biosimilar candidate (BAT2506) referencing Simponi.
Number 4: Organon said that it will do marketing but not research and development, Biogen and Bio-Thera moved forward with a tocilizumab candidate, and Lupin promoted a pegfilgrastim biosimilar.
Number 3: Investigators further elucidated the equivalence of a trastuzumab biosimilar vs Herceptin in HER2+ (human epidermal growth factor receptor 2–positive) breast cancer.
Number 2: When biosimilars emerged in oncology, oncologists dipped in a toe and then got serious, according to a retrospective study on usage and savings presented at ASCO 2021.
Number 1: Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, reported on his citizen petition to the FDA to rationalize testing of biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.